Aspects of Isotype Selection

  • Zehra KaymakcalanEmail author
  • Alexander Ibraghimov
  • Andrew G. Goodearl
  • Jochen G. Salfeld
Part of the Springer Protocols Handbooks book series (SPH)

The history of isotype selection for therapeutic antibodies clearly demonstrates that solid understanding of the biologic effects mediated by immunoglobulin (Ig) subclasses IgG1, IgG2, IgG3, and IgG4 and their variants is a prerequisite for optimal antibody development. The choices of isotype-constant regions for full-length antibody generation are becoming more complex by the availability of engineered variants and, in some cases, mixed isotypes. This review focuses on important lessons from preclinical studies, and clinical trials, which underscore that careful selection of isotypes is critical given their differential effects on antibody function. The molecular requirements vary for different mechanisms of action of therapeutic antibodies (eg, neutralizing, agonistic, conjugated), and IgG properties beneficial for one mechanism might be detrimental for another. Key isotype selection principles for optimal antibody development are reviewed, and case studies are discussed.


Effector Function Cell Depletion Constant Region IgG1 Isotype Therapeutic Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Editorial support was provided by Robin L. Stromberg, PhD, of Arbor Communications, Inc. (Ann Arbor, MI, USA) and funded by Abbott Laboratories.


  1. Anderson D, Chambers K, Hanna N, Leonard J, Reff M, Newman R, Baldoni J, Dunleavy D, Reddy M, Sweet R, Truneh A (1997) A primatized MAb to human CD4 causes receptor modulation without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Clin Immunol Immunopathol 84:73–84PubMedCrossRefGoogle Scholar
  2. Beenhouwer DO, Yoo EM, Lai CW, Rocha MA, Morrison SL (2007) Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection. Infect Immun 75:1424–1435PubMedCrossRefGoogle Scholar
  3. Blaich G, Janssen B, Roth G, Salfeld J (2007) Overview: differentiating issues in the development of macromolecules compared with small molecules. In: Gad SC (ed) Handbook of pharmaceutical biotechnology. John Wiley & Sons, Hoboken, pp 89–123CrossRefGoogle Scholar
  4. Bowles JA, Weiner GJ (2005) CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 304:88–99PubMedCrossRefGoogle Scholar
  5. Canfield SM, Morrison SL (1991) The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med 173:1483–1491PubMedCrossRefGoogle Scholar
  6. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285–4289PubMedCrossRefGoogle Scholar
  7. Casadevall A, Cleare W, Feldmesser M, Glatman-Freedman A, Goldman DL, Kozel TR, Lendvai N, Mukherjee J, Pirofski LA, Rivera J, Rosas AL, Scharff MD, Valadon P, Westin K, Zhong Z (1998) Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother 42:1437–1446PubMedGoogle Scholar
  8. Chamberlain AK, Desjarlais JR, Karki SB, Lazar GA, Vielmetter J, Yoder SC (2006) inventors; Xencor, Inc, assignee. Fc variants with altered binding to FcRn. US patent application 20,070,135,620Google Scholar
  9. Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A, Gevaert Y, Kreis H, Franchimont P, Bach JF (1990) In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49:697–702PubMedCrossRefGoogle Scholar
  10. Dall’Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H (2006) Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol 177:1129–1138PubMedGoogle Scholar
  11. Dillon TM, Ricci MS, Vezina C, Flynn GC, Liu YD, Rehder DS, Plant M, Henkle B, Li Y, Deechongkit S, Varnum B, Wypych J, Balland A, Bondarenko PV (2008) Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 283:16206–16215PubMedCrossRefGoogle Scholar
  12. Duncan AR, Winter G (1988) The binding site for C1q on IgG. Nature 332:738–740PubMedCrossRefGoogle Scholar
  13. Gillies SD, Lan Y, Williams S, Carr F, Forman S, Raubitschek A, Lo KM (2005) An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 105:3972–3978PubMedCrossRefGoogle Scholar
  14. Greenwood J, Clark M, Waldmann H (1993) Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 23:1098–1104PubMedCrossRefGoogle Scholar
  15. Guler-Gane G, Holgate R, Jermutus L, Levens J, Lund J, Stewart R, Thom A, Webster C (2008) inventors; MedImmune, assignee. Fc polypeptide variants obtained by ribosome display methodology. International patent application WO/2008/114011Google Scholar
  16. Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, Waldmann H (1983) Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 62:873–882PubMedGoogle Scholar
  17. Hale G, Dyer MJ, Clark MR, Phillips JM, Marcus R, Riechmann L, Winter G, Waldmann H (1988) Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 2:1394–1399PubMedCrossRefGoogle Scholar
  18. Hepburn TW, Totoritis MC, Davis CB (2003) Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis. Rheumatology (Oxford) 42:54–61CrossRefGoogle Scholar
  19. Herzog C, Walker C, Müller W, Rieber P, Reiter C, Riethmüller G, Wassmer P, Stockinger H, Madic O, Pichler WJ (1989) Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells. J Autoimmun 2:627–642PubMedCrossRefGoogle Scholar
  20. Hinton PR, Tsurushita N, Tso JY, Vasquez M, inventors; PDL BioPharma (2008) Inc, assignee. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis. US patent 7,361,740Google Scholar
  21. HUMIRA Biologic License Application (BLA 125057). Abbott Laboratories, Abbott Park, Accessed 11 Feb 2009
  22. Idusogie EE, Presta LG, Mulkerrin MG (2001) inventors; Genentech, Inc, assignee. Polypeptide variants. US patent 6194551Google Scholar
  23. International Immunogenetics Information System. Gene table: Human (Homo sapiens) IGHC. Cited 22 Jan 2009
  24. Isaacs JD, Wing MG, Greenwood JD, Hazleman BL, Hale G, Waldmann H (1996) A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin Exp Immunol 106:427–433PubMedCrossRefGoogle Scholar
  25. Jefferis R, Lund J, Goodall M (1995) Recognition sites on human IgG for Fc gamma receptors: the role of glycosylation. Immunol Lett 44:111–117PubMedCrossRefGoogle Scholar
  26. Jolliffe LK (1993) Humanized antibodies: enhancing therapeutic utility through antibody engineering. Int Rev Immunol 10:241–250PubMedCrossRefGoogle Scholar
  27. Kon OM, Sihra BS, Compton CH, Leonard TB, Kay AB, Barnes NC (1998) Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 352:1109–1113PubMedCrossRefGoogle Scholar
  28. Kung P, Goldstein G, Reinherz EL, Schlossman SF (1979) Monoclonal antibodies defining distinctive human T cell surface antigens. Science 206:347–349PubMedCrossRefGoogle Scholar
  29. Langer F, Ingersoll SB, Amirkhosravi A, Meyer T, Siddiqui FA, Ahmad S, Walker JM, Amaya M, Desai H, Francis JL (2005) The role of CD40 in CD40L- and antibody-mediated platelet activation. Thromb Haemost 93:1137–1146PubMedGoogle Scholar
  30. Lazar GA, Chirino AJ, Wei D, Desjarlais JR, Doberstein SK, Hayes RJ, Karki SB, Vafa O (2008) inventors; Xencor, Inc, assignee. Optimized Fc variants. US patent 7317091Google Scholar
  31. Lendvai N, Qu XW, Hsueh W, Casadevall A (2000) Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans-infected mice. J Immunol 164:4367–4374PubMedGoogle Scholar
  32. Liu YD, Chen X, Enk JZ, Plant M, Dillon TM, Flynn GC (2008) Human IgG2 antibody disulfide rearrangement in vivo. J Biol Chem 283:29266–29272PubMedCrossRefGoogle Scholar
  33. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J (2003) In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101:949–954PubMedCrossRefGoogle Scholar
  34. McDonagh CF, Kim KM, Turcott E, Brown LL, Westendorf L, Feist T, Sussman D, Stone I, Anderson M, Miyamoto J, Lyon R, Alley SC, Gerber HP, Carter PJ (2008) Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol Cancer Ther 7:2913–2923PubMedCrossRefGoogle Scholar
  35. McLean GR, Torres M, Elguezabal N, Nakouzi A, Casadevall A (2002) Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J Immunol 169:1379–1386PubMedGoogle Scholar
  36. Mould DR, Davis CB, Minthorn EA, Kwok DC, Elliott MJ, Luggen ME, Totoritis MC (1999) A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clin Pharmacol Ther 66:246–257PubMedCrossRefGoogle Scholar
  37. Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K, Wakitani M, Ohta S, Satoh M, Shitara K, Niwa R (2008) Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 68:3863–3872PubMedCrossRefGoogle Scholar
  38. Newman R, Hariharan K, Reff M, Anderson DR, Braslawsky G, Santoro D, Hanna N, Bugelski PJ, Brigham-Burke M, Crysler C, Gagnon RC, Dal Monte P, Doyle ML, Hensley PC, Reddy MP, Sweet RW, Truneh A (2001) Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees. Clin Immunol 98:164–174PubMedCrossRefGoogle Scholar
  39. Nussbaum G, Cleare W, Casadevall A, Scharff MD, Valadon P (1997) Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med 185:685–694PubMedCrossRefGoogle Scholar
  40. Pop LM, Liu X, Ghetie V, Vitetta ES (2005) The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life. Int Immunopharmacol 5:1279–1290PubMedCrossRefGoogle Scholar
  41. Prahl JW (1967) The C-terminal sequences of the heavy chains of human immunoglobulin G myeloma proteins of differing isotopes and allotypes. Biochem J 105:1019–1028PubMedGoogle Scholar
  42. Presta L (2008) inventor; Genentech, Inc, assignee. Polypeptide variants with altered effector functions. US patent 7371826Google Scholar
  43. Puan KJ, Jin C, Wang H, Sarikonda G, Raker AM, Lee HK, Samuelson MI, Märker-Hermann E, Pasa-Tolic L, Nieves E, Giner JL, Kuzuyama T, Morita CT (2007) Preferential recognition of a microbial metabolite by human Vgamma2Vdelta2 T cells. Int Immunol 19:657–673PubMedCrossRefGoogle Scholar
  44. Reddy MP, Kinney CA, Chaikin MA, Payne A, Fishman-Lobell J, Tsui P, Dal Monte PR, Doyle ML, Brigham-Burke MR, Anderson D, Reff M, Newman R, Hanna N, Sweet RW, Truneh A (2000) Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol 164:1925–1933PubMedGoogle Scholar
  45. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445PubMedGoogle Scholar
  46. Reichert JM (2008) Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 9:423–430PubMedCrossRefGoogle Scholar
  47. Salfeld JG (2007) Isotype selection in antibody engineering. Nat Biotechnol 25:1369–1372PubMedCrossRefGoogle Scholar
  48. Shan D, Ledbetter JA, Press OW (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644–1652PubMedGoogle Scholar
  49. Sharma A, Davis CB, Tobia LA, Kwok DC, Tucci MG, Gore ER, Herzyk DJ, Hart TK (2000) Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther 293:33–41PubMedGoogle Scholar
  50. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276:6591–6604PubMedCrossRefGoogle Scholar
  51. Stavenhagen J, Vijh S, Rankin C, Gorlatov S, Huang L (2008) inventors; Macrogenics, Inc, assignee. Identification and engineering of antibodies with variant Fc regions and methods of using same. US patent 7,355,008Google Scholar
  52. Suitters AJ, Foulkes R, Opal SM, Palardy JE, Emtage JS, Rolfe M, Stephens S, Morgan A, Holt AR, Chaplin LC, Shaw NE, Nesbitt AM, Bodmer MW (1994) Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock. J Exp Med 179:849–856PubMedCrossRefGoogle Scholar
  53. Summary of Tysabri Post-Marketing Commitments. Cited 22 Jan 2009
  54. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199:1659–1669PubMedCrossRefGoogle Scholar
  55. Valabrega G, Montemurro F, Aglietta M (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18:977–984PubMedCrossRefGoogle Scholar
  56. van de Winkel J, Vink T, Schuurman J, Parren P, Aalberse R, van der Neut Kolfshoten M (2008) inventors; Genmab A/S, assignee. Stable IgG4 antibodies. International patent application WO/2008/145142Google Scholar
  57. van der Lubbe PA, Reiter C, Breedveld FC, Krüger K, Schattenkirchner M, Sanders ME, Riethmüller G (1993) Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum 36:1375–1379PubMedCrossRefGoogle Scholar
  58. van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, De Baets MH, van de Winkel JG, Aalberse RC, Parren PW (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317:1554–1557PubMedCrossRefGoogle Scholar
  59. Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, Ghetie V, Uhr JW, Thorpe PE (1991) Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51:4052–4058PubMedGoogle Scholar
  60. Wagner K, Schulz P, Scholz A, Wiedenmann B, Menrad A (2008) The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res 14:4951–4960PubMedCrossRefGoogle Scholar
  61. Wang SY, Weiner G (2008) Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther 8:759–768PubMedCrossRefGoogle Scholar
  62. Wing MG, Moreau T, Greenwood J, Smith RM, Hale G, Isaacs J, Waldmann H, Lachmann PJ, Compston A (1996) Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 98:2819–2826PubMedCrossRefGoogle Scholar
  63. Woodle ES, Thistlethwaite JR, Jolliffe LK, Zivin RA, Collins A, Adair JR, Bodmer M, Athwal D, Alegre ML, Bluestone JA (1992) Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression. J Immunol 148:2756–2763PubMedGoogle Scholar
  64. Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O’Laughlin R, Peace D, Jollife LK, Haverty T, Bluestone JA, Thistlethwaite JR Jr (1999) Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68:608–616PubMedCrossRefGoogle Scholar
  65. Wu AM, Senter PD (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137–1146PubMedCrossRefGoogle Scholar
  66. Wypych J, Li M, Guo A, Zhang Z, Martinez T, Allen MJ, Fodor S, Kelner DN, Flynn GC, Liu YD, Bondarenko PV, Ricci MS, Dillon TM, Balland A (2008) Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem 283:16194–16205PubMedCrossRefGoogle Scholar
  67. Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PW, Bluestone JA, Jolliffe LK, Zivin RA (2000) In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 200:16–26PubMedCrossRefGoogle Scholar
  68. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62:4132–4141PubMedGoogle Scholar
  69. Yednock T (2007) inventor; Elan Pharmaceuticals, Inc, assignee. Methods of treating inflammatory and autoimmune diseases with natalizumab. International patent application WO/2007/103112Google Scholar
  70. Yoo EM, Wims LA, Chan LA, Morrison SL (2003) Human IgG2 can form covalent dimers. J Immunol 170:3134–3138PubMedGoogle Scholar
  71. Zebedee SL, Koduri RK, Mukherjee J, Mukherjee S, Lee S, Sauer DF, Scharff MD, Casadevall A (1994) Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob Agents Chemother 38:1507–1514PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Zehra Kaymakcalan
    • 1
    Email author
  • Alexander Ibraghimov
    • 1
  • Andrew G. Goodearl
    • 1
  • Jochen G. Salfeld
    • 1
  1. 1.Department of BiologicsAbbott Bioresearch CenterWorcesterUSA

Personalised recommendations